[2008] 1.1.8 Use the QRISK2 risk assessment tool to assess CVD risk for the primary prevention of CVD in people up to and including age 84 years. [2014] 1.1.9 Do not use a risk assessment tool to assess CVD risk in people with type 1 diabetes. See recommendations 1.3.23, 1.3.24 and 1.3.25 for advice on treatment with statins for people with type 1 diabetes. [2014] 1.1.10 Use the QRISK2 risk assessment tool to assess CVD risk in people with 1.1.11 Do not use a risk assessment tool to assess CVD risk in people with an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2 and/or albuminuria. These people are at increased risk of CVD. See the recommendation on advice on treatment with statins for people with chronic kidney disease (CKD). [2014] People on renal replacement therapy are outside the scope of this guideline. 1.1.12 Complete as many fields of the risk assessment tool as possible. [2014] 1.1.13 Routinely record ethnicity, body mass index (BMI) and family history of premature CVD in medical records. [2008] 1.1.14 Consider socioeconomic status as an additional factor that contributes to CVD risk. [2008] 1.1.15 Do not use a risk assessment tool for people with pre-existing CVD. 1.1.16 Do not use a risk assessment tool for people who are at high risk of developing CVD because of familial hypercholesterolaemia (see NICE's guideline on familial hypercholesterolaemia) or other inherited disorders of lipid metabolism. [2008, amended 2014] 1.1.17 When using the risk score to inform drug treatment decisions, particularly if it is near to the threshold for treatment, take into account other factors that: may predispose the person to premature CVD and may not be included in calculated risk scores. 